[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=67e0dae03adba106029fa4b28cf77a1cea0f9c8b34b5cb701e96291b7a1680f1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757608740,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 136716042,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=67e0dae03adba106029fa4b28cf77a1cea0f9c8b34b5cb701e96291b7a1680f1"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis",
    "summary": "BOSTON, September 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role \"in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.\" Dr. Negulescu is one of three awardees, alongside Jesús",
    "url": "https://finnhub.io/api/news?id=a041fe0fb25fc7215481c5f92eea5bd7eeb24b0593d84e79b6213d3920a4c78f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757599500,
      "headline": "Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis",
      "id": 136704205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, September 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role \"in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.\" Dr. Negulescu is one of three awardees, alongside Jesús",
      "url": "https://finnhub.io/api/news?id=a041fe0fb25fc7215481c5f92eea5bd7eeb24b0593d84e79b6213d3920a4c78f"
    }
  }
]